诺和诺德基金会参投的生物科技公司Hemab(COAG.US)拟赴美IPO，最高募资2.12亿美元

智通财经04-28

智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.(COAG.US)正寻求在美国首次公开募股(IPO)中最高融资2.12亿美元。根据该公司周一提交给美国证券交易委员会(SEC)的招股文件，Hemab计划发行1180万股股份，发行价格区间为每股16至18美元。按发行价上限计算，这家总部位于马萨诸塞州剑桥市的公司市值将约为7.057亿美元(以招股...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2630437375?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-28 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630437375","market":"hk","top_or_hot":-1,"title":"诺和诺德基金会参投的生物科技公司Hemab(COAG.US)拟赴美IPO，最高募资2.12亿美元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.(COAG.US)正寻求在美国首次公开募股(IPO)中最高融资2.12亿美元。根据该公司周一提交给美国证券交易委员会(SEC)的招股文件，Hemab计划发行1180万股股份，发行价格区间为每股16至18美元。按发行价上限计算，这家总部位于马萨诸塞州剑桥市的公司市值将约为7.057亿美元(以招股...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1435195.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德基金会参投的生物科技公司Hemab(COAG.US)拟赴美IPO，最高募资2.12亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德基金会参投的生物科技公司Hemab(COAG.US)拟赴美IPO，最高募资2.12亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 16:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1435195.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.(COAG.US)正寻求在美国首次公开募股(IPO)中最高融资2.12亿美元。根据该公司周一提交给美国证券交易委员会(SEC)的招股文件，Hemab计划发行1180万股股份，发行价格区间为每股16至18美元。按发行价上限计算，这家总部位于马萨诸塞州剑桥市的公司市值将约为7.057亿美元(以招股...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1435195.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1435195.html","article_id":"2630437375","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630437375","pubTimestamp":1777363239,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.正寻求在美国首次公开募股中最高融资2.12亿美元。此次生物科技公司IPO的背景是，投资者对减肥药物开发商Kailera Therapeutics Inc.给予了热烈反响——该公司于本月初上市，募资7.19亿美元，创下2021年以来该行业在美国最大的IPO记录。招股文件还显示，在本次发行前，RA Capital Management的关联实体与诺和诺德基金会分别持有Hemab 18%和15%的股份。截至2025年12月31日，公司持有现金及现金等价物共1.85亿美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","BK4588":"碎股","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","COAG":"Hemab Therapeutics Holdings, Inc.","BK4581":"高盛持仓","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","NVOX":"2倍做多NVO ETF-Defiance","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药"},"translate_title":"Hemab (COAG.US), a biotechnology company invested by Novo Nordisk Foundation, plans to IPO in the United States, raising a maximum of $212 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVO":1.85,"NVOX":0.6,"COAG":1.98},"content_text":"智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.(COAG.US)正寻求在美国首次公开募股(IPO)中最高融资2.12亿美元。根据该公司周一提交给美国证券交易委员会(SEC)的招股文件，Hemab计划发行1180万股股份，发行价格区间为每股16至18美元。按发行价上限计算，这家总部位于马萨诸塞州剑桥市的公司市值将约为7.057亿美元(以招股文件所列流通股为基准)。招股文件显示，Hemab正在开发针对凝血障碍疾病的疗法，涵盖格兰茨曼血小板无力症及血管性血友病等适应症。该公司于今年3月宣布，其用于治疗格兰茨曼血小板无力症的疗法已获得美国食品药品监督管理局(FDA)授予的突破性疗法认定。为筹备此次上市，Hemab此前曾以丹麦法律下的Hemab Aps名义运营，后更名重组。此次生物科技公司IPO的背景是，投资者对减肥药物开发商Kailera Therapeutics Inc.给予了热烈反响——该公司于本月初上市，募资7.19亿美元，创下2021年以来该行业在美国最大的IPO记录。据市场汇编的数据，今年以来，医疗健康领域新股在美国交易所已累计募资33亿美元，远高于2025年同期的14亿美元。招股文件还显示，在本次发行前，RA Capital Management的关联实体与诺和诺德基金会分别持有Hemab 18%和15%的股份。Hemab在2025年录得净亏损6400万美元，相比之下，上年同期净亏损为4900万美元。截至2025年12月31日，公司持有现金及现金等价物共1.85亿美元。本次IPO的主承销商为高盛集团、杰富瑞金融集团以及Evercore Inc.。公司计划在纳斯达克全球精选市场上市，股票代码为“COAG”。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630437375","isCrawlerRequest":true}